Literature DB >> 27004573

Laboratory diagnosis of human visceral leishmaniasis.

Hercules Sakkas1, Constantina Gartzonika, Stamatina Levidiotou.   

Abstract

Visceral leishmaniasis (VL), caused by the Leishmania donovani complex, is a vector-borne systemic disease, with a worldwide distribution causing high morbidity and mortality in the developing world. VL patients may be asymptomatic or they may present symptoms and findings of a systemic infection. The positive predictive value of clinical diagnosis in patients with typical symptoms is usually high, but more often, the signs and symptoms are inconclusive and mistaken with other co-endemic diseases. The fact that HIV co-infections often produce atypical presentations and the heterogeneity of Leishmania species, which is common in many endemic regions, also complicate the diagnosis. Despite that, some of the parasitological methods are still considered to be the reference standard for VL diagnosis due to their specificity. The development of serological and molecular tests has further enhanced the diagnostic approach of VL. Recombinant antigens have improved the performance of serodiagnostic tests, with DAT and the rK39 antigen based immunochromatographic test being the most appropriate methods for the serological diagnosis of VL. Molecular techniques, despite the fact that their implementation is often difficult and infeasible, have become increasingly relevant due to remarkable sensitivity and specificity, and to the variability of tested samples. Quantitative polymerase chain reaction (qPCR) has been shown to be superior than conventional PCR for the differentiation between active VL and asymptomatic infections, such as for the detection of VL-HIV coinfection. This review summarizes the available methods with their applications in the diagnosis of VL, and focuses on the recent developments in VL diagnostics.

Entities:  

Mesh:

Year:  2016        PMID: 27004573

Source DB:  PubMed          Journal:  J Vector Borne Dis        ISSN: 0972-9062            Impact factor:   1.688


  29 in total

1.  Evaluation of a hypothetical protein for serodiagnosis and as a potential marker for post-treatment serological evaluation of tegumentary leishmaniasis patients.

Authors:  Mariana Pedrosa Lima; Lourena Emanuele Costa; Mariana Costa Duarte; Daniel Menezes-Souza; Beatriz Cristina Silveira Salles; Thaís Teodoro de Oliveira Santos; Fernanda Fonseca Ramos; Miguel Angel Chávez-Fumagalli; Amanda Christine Silva Kursancew; Roberta Passamani Ambrósio; Bruno Mendes Roatt; Ricardo Andrez Machado-de-Ávila; Denise Utsch Gonçalves; Eduardo Antonio Ferraz Coelho
Journal:  Parasitol Res       Date:  2017-02-01       Impact factor: 2.289

2.  Asymptomatic Visceral Leishmania infantum Infection in US Soldiers Deployed to Iraq.

Authors:  Rupal M Mody; Ines Lakhal-Naouar; Jeffrey E Sherwood; Nancy L Koles; Dutchabong Shaw; Daniel P Bigley; Edgie-Mark A Co; Nathanial K Copeland; Linda L Jagodzinski; Rami M Mukbel; Rebecca A Smiley; Robert C Duncan; Shaden Kamhawi; Selma M B Jeronimo; Robert F DeFraites; Naomi E Aronson
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

3.  Subclinical Leishmania infection in patients with rheumatic diseases under biological drugs.

Authors:  Martina Maritati; Alessandro Trentini; Gregory Michel; Tiziana Bellini; Shawgi Almugadam; Stefania Hanau; Marcello Govoni; Pierre Marty; Carlo Contini
Journal:  Infection       Date:  2018-08-10       Impact factor: 3.553

4.  Performance of two immunochromatographic tests for diagnosis of visceral leishmaniasis in patients coinfected with HIV.

Authors:  Mauro Roberto Biá da Silva; Natália Alberto Alves Brandão; Marco Colovati; Margella Marconcine Pinheiro de Sousa; Larissa Coelho de Lima; Miriam Leandro Dorta; Fátima Ribeiro-Dias; Dorcas Lamounier Costa; Carlos Henrique Nery Costa; Milton Adriano Pelli de Oliveira
Journal:  Parasitol Res       Date:  2017-12-21       Impact factor: 2.289

5.  Detection and Differentiation of Leishmania spp. in Clinical Specimens by Use of a SYBR Green-Based Real-Time PCR Assay.

Authors:  Marcos E de Almeida; Ozgur Koru; Francis Steurer; Barbara L Herwaldt; Alexandre J da Silva
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

Review 6.  What do we know about the role of regulatory B cells (Breg) during the course of infection of two major parasitic diseases, malaria and leishmaniasis?

Authors:  Roberta Reis Soares; Luciana Maria Ribeiro Antinarelli; Clarice Abramo; Gilson Costa Macedo; Elaine Soares Coimbra; Kézia Katiani Gorza Scopel
Journal:  Pathog Glob Health       Date:  2017-03-29       Impact factor: 2.894

7.  Recombinant Cysteine Proteinase B from Leishmania braziliensis and Its Domains: Promising Antigens for Serodiagnosis of Cutaneous and Visceral Leishmaniasis in Dogs.

Authors:  A E Bivona; L Czentner; A Sanchez Alberti; N Cerny; A C Cardoso Landaburu; C Nevot; O Estévez; J D Marco; M A Basombrio; E L Malchiodi; S I Cazorla
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

8.  High frequency of subclinical Leishmania infection among HIV-infected patients living in the endemic areas of visceral leishmaniasis in Fars province, southern Iran.

Authors:  Z Rezaei; B Sarkari; M Dehghani; A Layegh Gigloo; M Afrashteh
Journal:  Parasitol Res       Date:  2018-06-02       Impact factor: 2.289

9.  Prevalence of and Factors Associated with Negative Microscopic Diagnosis of Cutaneous Leishmaniasis in Rural Peru.

Authors:  Ryan Lamm; Clark Alves; Grace Perrotta; Meagan Murphy; Catherine Messina; Juan F Sanchez; Erika Perez; Luis Angel Rosales; Andres G Lescano; Edward Smith; Hugo Valdivia; Jack Fuhrer; Sarah-Blythe Ballard
Journal:  Am J Trop Med Hyg       Date:  2018-05-31       Impact factor: 2.345

10.  Improved Performance of ELISA and Immunochromatographic Tests Using a New Chimeric A2-Based Protein for Human Visceral Leishmaniasis Diagnosis.

Authors:  Maria Marta Figueiredo; Anna R R Dos Santos; Lara C Godoi; Natália S de Castro; Bruno C de Andrade; Sarah A R Sergio; Selma M B Jerônimo; Edward J de Oliveira; Ruth T Valencia-Portillo; Lucilândia M Bezerra; Hiro Goto; Maria C A Sanchez; Caroline Junqueira; Santuza M R Teixeira; Flávio G da Fonseca; Ricardo T Gazzinelli; Ana Paula Fernandes
Journal:  J Immunol Res       Date:  2021-04-28       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.